Eurofins: 9m sales down 4.2%
(CercleFinance.com) - Eurofins Scientific has reported 9m 2023 revenues that are down 4.
2% to E4.82bn, due to a drop in Covid-19 test and reagent revenues, as well as a negative currency effect (-1.6%) and one less working day.
Adjusted for these factors, the bioanalytical services provider's revenues from its core business rose by 7.3% organically over the period, including 7.6% growth in Q3 alone.
Eurofins also confirms its 2023 targets of adjusted EBITDA of E1.32bn to E1.37bn and revenues of E6.45bn to E6.55bn, alongside its 2027 forecasts of an adjusted EBITDA margin of 24% and revenues approaching E10bn.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
2% to E4.82bn, due to a drop in Covid-19 test and reagent revenues, as well as a negative currency effect (-1.6%) and one less working day.
Adjusted for these factors, the bioanalytical services provider's revenues from its core business rose by 7.3% organically over the period, including 7.6% growth in Q3 alone.
Eurofins also confirms its 2023 targets of adjusted EBITDA of E1.32bn to E1.37bn and revenues of E6.45bn to E6.55bn, alongside its 2027 forecasts of an adjusted EBITDA margin of 24% and revenues approaching E10bn.
Copyright (c) 2023 CercleFinance.com. All rights reserved.